FDA New Guidance on Opioids Drawing Response

FDA New Guidance on Opioids Drawing Response

Publication date: Apr 12, 2019

The FDA’s safety announcement this week that says it has identified harm reported from sudden discontinuation of opioid pain medicines and is requiring label changes to guide prescribers on gradual, individualized tapering was generally praised.

-As several past presidents of the American Academy of Pain Medicine and other prominent medical professionals have pointed out in a December 2018 letter to the Governor of Oregon, there are no published trials data that establish benefit to legacy patients from mandated tapering of opioid therapy.

-I cannot believe that these -findings” were a surprise to anyone that deals with opioids,” wrote Dr. Mark Helfand to the National Pain Report.

Gary lives in Virginia and wrote to the National Pain Report that the FDA word getting out needs to happen fast.

Concepts Keywords
Analgesic Pain management
Australia Pain
CDC Opioids
Charlottesville Perception
Dentist Health
FDA Intractable pain
Governor Pain management
Iatrogenic Analgesic
Lynchburg
Narcotic
Opioid
Opioids
Oregon
Pain
Pain Management
Pharmacies
PhD
Roanoke
Stanford
Virginia

Semantics

Type Source Name
disease MESH death
gene UNIPROT MAP6
gene UNIPROT FBXW7
gene UNIPROT MARK1
gene UNIPROT EHD1
gene UNIPROT PTPN5
gene UNIPROT BEST1
gene UNIPROT PDC
disease MESH narcotic
gene UNIPROT TNFSF13
gene UNIPROT ANP32B
gene UNIPROT FASTK

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *